CTOs on the Move

Chicago Hospital Risk Pooling Program

www.mchc.com

 
Chicago Hospital Risk Pooling Program is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mchc.com
  • 222 S Riverside Plz Ste 1900
    Chicago, IL USA 60606
  • Phone: 312.906.6000

Executives

Name Title Contact Details

Similar Companies

Cover Oregon

Cover Oregon was created for Oregonians by Oregonians. We're one of the first states to build our own health insurance marketplace. We're setting the standard for making health coverage more accessible and easier to understand. We're improving the health of all Oregonians by providing health coverage options, increasing access to information and fostering quality and value in the health care system.

SNDL

Sundial believes in health, happiness and personal well-being. Our cannabis is carefully cultivated for modern consumers—people looking for a natural alternative that fits todays active lifestyles. We are a licensed cannabis producer based in Alberta. We combine tried-and-true heartland farming with innovative horticultural techniques to grow a select range of cannabis strains. Our focus is on consistency—a pure cannabis experience that our customers can trust and count on.

Convergence Health

Convergence Health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Incline Village, NV. To find more information about Convergence Health, please visit www.convergencehealth.com

Quality Health

Quality Health is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oklahoma Medical Research Foundation

Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.